Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
종목 코드 CDIO
회사 이름Cardio Diagnostics Holdings Inc
상장일Nov 23, 2021
CEODr. Meeshanthini V. (Meesha) Dogan, Ph.D.
직원 수13
유형Ordinary Share
회계 연도 종료Nov 23
주소311 W. Superior Street
도시CHICAGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호60645
전화18552269991
웹사이트
종목 코드 CDIO
상장일Nov 23, 2021
CEODr. Meeshanthini V. (Meesha) Dogan, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음